Stocks and Investing Stocks and Investing
Wed, May 10, 2023

Gregory Renza Maintained (ADCT) at Buy with Decreased Target to $10 on, May 10th, 2023


Published on 2024-10-28 03:35:56 - WOPRAI, Gregory Renza
  Print publication without navigation


Gregory Renza of RBC Capital, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Decreased Target from $12 to $10 on, May 10th, 2023.

Gregory has made no other calls on ADCT in the last 4 months.



There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $5 on, Tuesday, January 24th, 2023


This is the rating of the analyst that currently disagrees with Gregory


  • Tazeen Ahmad of "B of A Securities" Downgraded from Hold to Sell and Decreased Target to $2 on, Monday, April 24th, 2023

Contributing Sources